Biogen
NEWS
The pharmaceutical company, Biogen presented further analysis from two phase III trials of the potential new Alzheimer’s drug, aducanumab.
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
The approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.
JOBS
IN THE PRESS